QLC1401 with CDK4/6 or mTOR inhibitors for advanced breast cancer
Part of Cancer clinical trials.
This trial tests a new drug called QLC1401 combined with either CDK4/6 or mTOR inhibitors (targeted therapies that help stop cancer cell growth) in people with advanced breast cancer that is ER-positive (fueled by estrogen) and HER2-negative. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have advanced breast cancer that is ER-positive and HER2-negative.
- You are postmenopausal.
- You are generally able to care for yourself (ECOG score 0-1).
- You have at least one tumor that can be measured on scans.
- You have adequate organ function (kidney, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (iparomlimab and tuvonralimab, also called QL1706) for people with advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if standard treatments have stopped working.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This trial tests a new drug called QLS1304 combined with hormone therapy for people with ER-positive, HER2-negative breast cancer that has spread or come back and no longer responds to hormone therapy alone. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new immunotherapy drug (QL1706) combined with a short course of common chemotherapy (anthracyclines or taxanes) for people with early-stage triple-negative breast cancer. The goal is to see if this combination is safe and helps shrink the tumor before surgery.
This trial tests a new combination of drugs for people with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and improve outcomes.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.